Total-body [ Ga]Ga-PSMA-11 PET/CT Improves Detection Rate Compared with Conventional [ Ga]Ga-PSMA-11 PET/CT in Patients with Biochemical Recurrent Prostate Cancer

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2023 Aug 14

PMID 37578502

Authors

Yining Wang

Zijun Chen

Yinjie Zhu

Haitao Zhao

Lianghua Li

Gang Huang

Wei Xue

Ruohua Chen

Jianjun Liu

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to assess whether total-body [ Ga]Ga-PSMA-11 PET/CT could improve the detection rate compared with conventional [ Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer.

Methods: Two hundred biochemical recurrent prostate cancer patients with similar clinicopathological characteristics were included, of whom 100 patients underwent early total-body [ Ga]Ga-PSMA-11 PET/CT and diuretic-delayed total-body [ Ga]Ga-PSMA-11 PET/CT, and the other 100 patients received early conventional [ Ga]Ga-PSMA-11 PET/CT and diuretic-delayed conventional [ Ga]Ga-PSMA-11 PET/CT. The detection rates of total-body [ Ga]Ga-PSMA-11 PET/CT and conventional [ Ga]Ga-PSMA-11 PET/CT were compared using a chi-square test and stratified analysis. The image quality of total-body [ Ga]Ga-PSMA PET/CT and conventional [ Ga]Ga-PSMA-11 PET/CT was compared based on subjective scoring and objective parameters. Subjective scoring was conducted from background noise and lesion prominence using a 5-point scale. Objective parameters were evaluated by SUVmax, SUVmean, the standard deviation (SD) of SUV, and the signal-to-noise ratio (SNR) of liver and gluteus maximus. The SUVmax of the recurrent lesions was also measured.

Results: The liver SD of the total-body [ Ga]Ga-PSMA-11 PET/CT was significantly lower than that of conventional [ Ga]Ga-PSMA-11 PET/CT, the SNR was significantly higher than that of conventional [ Ga]Ga-PSMA-11 PET/CT, and the subjective evaluation was significantly better than that of conventional [ Ga]Ga-PSMA-11 PET/CT. The detection rate of total-body [ Ga]Ga-PSMA PET/CT for biochemical recurrence of prostate cancer was significantly higher than that of conventional [ Ga]Ga-PSMA-11 PET/CT (91.0% vs. 74.0%, P = 0.003). Total-body [ Ga]Ga-PSMA-11 PET/CT had better detection efficiency for patients with a Gleason score ≤ 8 or PSA ≤ 2 ng/ml. The advantages of diuretic-delayed total-body [ Ga]Ga-PSMA-11 PET/CT were more obvious.

Conclusion: Total-body [ Ga]Ga-PSMA-11 PET/CT could significantly improve the detection rate compared with conventional [ Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer.

Citing Articles

Comparison of clinical performance between late and standard total-body [ Ga]Ga-PSMA-11 in biochemical recurrent prostate cancer.

Chen Q, Dong L, Xu L, Zhao H, Li L, Huang G Eur J Nucl Med Mol Imaging. 2024; 52(4):1249-1256.

PMID: 39540904 DOI: 10.1007/s00259-024-06980-8.

The superior detection rate of total-body [Ga]Ga-PSMA-11 PET/CT compared to short axial field-of-view [Ga]Ga-PSMA-11 PET/CT for early recurrent prostate cancer patients with PSA < 0.2 ng/mL after radical prostatectomy.

Wang Y, Dong L, Zhao H, Li L, Huang G, Xue W Eur J Nucl Med Mol Imaging. 2024; 51(8):2484-2494.

PMID: 38514483 DOI: 10.1007/s00259-024-06674-1.

Combined whole-body dynamic and static PET/CT with low-dose [F]PSMA-1007 in prostate cancer patients.

Sachpekidis C, Pan L, Groezinger M, Strauss D, Dimitrakopoulou-Strauss A Eur J Nucl Med Mol Imaging. 2024; 51(7):2137-2150.

PMID: 38286936 PMC: 11139746. DOI: 10.1007/s00259-024-06620-1.

References

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Isbarn H, Wanner M, Salomon G, Steuber T, Schlomm T, Kollermann J . Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU Int. 2009; 106(1):37-43. DOI: 10.1111/j.1464-410X.2009.09134.x. View

Zhang X, Cherry S, Xie Z, Shi H, Badawi R, Qi J . Subsecond total-body imaging using ultrasensitive positron emission tomography. Proc Natl Acad Sci U S A. 2020; 117(5):2265-2267. PMC: 7007535. DOI: 10.1073/pnas.1917379117. View

Badawi R, Shi H, Hu P, Chen S, Xu T, Price P . First Human Imaging Studies with the EXPLORER Total-Body PET Scanner. J Nucl Med. 2019; 60(3):299-303. PMC: 6424228. DOI: 10.2967/jnumed.119.226498. View

Zhang X, Xie Z, Eric Berg , Judenhofer M, Liu W, Xu T . Total-Body Dynamic Reconstruction and Parametric Imaging on the uEXPLORER. J Nucl Med. 2019; 61(2):285-291. PMC: 8801950. DOI: 10.2967/jnumed.119.230565. View

Cherry S, Jones T, Karp J, Qi J, Moses W, Badawi R . Total-Body PET: Maximizing Sensitivity to Create New Opportunities for Clinical Research and Patient Care. J Nucl Med. 2017; 59(1):3-12. PMC: 5750522. DOI: 10.2967/jnumed.116.184028. View

Zhang X, Zhou J, Cherry S, Badawi R, Qi J . Quantitative image reconstruction for total-body PET imaging using the 2-meter long EXPLORER scanner. Phys Med Biol. 2017; 62(6):2465-2485. PMC: 5524562. DOI: 10.1088/1361-6560/aa5e46. View

Tan H, Sui X, Yin H, Yu H, Gu Y, Chen S . Total-body PET/CT using half-dose FDG and compared with conventional PET/CT using full-dose FDG in lung cancer. Eur J Nucl Med Mol Imaging. 2020; 48(6):1966-1975. DOI: 10.1007/s00259-020-05091-4. View

Zhao Y, Li Y, Chen T, Zhang W, Wang L, Feng J . Image quality and lesion detectability in low-dose pediatric F-FDG scans using total-body PET/CT. Eur J Nucl Med Mol Imaging. 2021; 48(11):3378-3385. DOI: 10.1007/s00259-021-05304-4. View

10.

Zhang Y, Hu P, Wu R, Gu Y, Chen S, Yu H . The image quality, lesion detectability, and acquisition time of F-FDG total-body PET/CT in oncological patients. Eur J Nucl Med Mol Imaging. 2020; 47(11):2507-2515. DOI: 10.1007/s00259-020-04823-w. View

11.

Fu F, Li X, Wu Y, Xu J, Bai Y, Gao Y . Total-body dynamic PET/CT of micro-metastatic lymph node in a patient with lung cancer. Eur J Nucl Med Mol Imaging. 2021; 48(5):1678-1679. DOI: 10.1007/s00259-020-05121-1. View

12.

Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel F, Hartenbach M . Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J Nucl Med. 2017; 59(3):469-478. DOI: 10.2967/jnumed.117.198119. View

13.

van Sluis J, Boellaard R, Somasundaram A, van Snick P, Borra R, Dierckx R . Image Quality and Semiquantitative Measurements on the Biograph Vision PET/CT System: Initial Experiences and Comparison with the Biograph mCT. J Nucl Med. 2019; 61(1):129-135. DOI: 10.2967/jnumed.119.227801. View

14.

Chen W, Liu L, Li Y, Li S, Li Z, Zhang W . Evaluation of pediatric malignancies using total-body PET/CT with half-dose [F]-FDG. Eur J Nucl Med Mol Imaging. 2022; 49(12):4145-4155. DOI: 10.1007/s00259-022-05893-8. View

15.

Van den Broeck T, van den Bergh R, Briers E, Cornford P, Cumberbatch M, Tilki D . Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. Eur Urol Focus. 2019; 6(2):231-234. DOI: 10.1016/j.euf.2019.06.004. View

16.

Hohberg M, Kobe C, Tager P, Hammes J, Schmidt M, Dietlein F . Combined Early and Late [Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels. Mol Imaging Biol. 2018; 21(3):558-566. DOI: 10.1007/s11307-018-1263-2. View

17.

Alberts I, Sachpekidis C, Gourni E, Boxler S, Gross T, Thalmann G . Dynamic patterns of [Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2019; 47(1):160-167. DOI: 10.1007/s00259-019-04545-8. View

18.

Alberts I, Niklas-Hunermund J, Sachpekidis C, Zacho H, Mingels C, Dijkstra L . Combination of Forced Diuresis with Additional Late Imaging in Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake. J Nucl Med. 2021; 62(9):1252-1257. DOI: 10.2967/jnumed.120.257741. View

19.

Kunikowska J, Pelka K, Tayara O, Krolicki L . Ga-68-PSMA-11 PET/CT in Patients with Biochemical Recurrence of Prostate Cancer after Primary Treatment with Curative Intent-Impact of Delayed Imaging. J Clin Med. 2022; 11(12). PMC: 9225064. DOI: 10.3390/jcm11123311. View

20.

Rouviere O, Vitry T, Lyonnet D . Imaging of prostate cancer local recurrences: why and how?. Eur Radiol. 2009; 20(5):1254-66. DOI: 10.1007/s00330-009-1647-4. View